ClinicalTrials.gg
CompletedNCT00555672Updated Dec 19, 2011Results posted

Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer

A Phase 1 interventional study of 5-fluorouracil and cisplatin in Stomach Neoplasms, sponsored by Pfizer. Completed at 3 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-12-19.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing fluorouracil in Stomach Neoplasms — 6 open to participants now, 8 under way, 1 of them phase 3. Fluorouracil · Stomach Neoplasms.

Enrollment
49th of 73
34 · median 50
Started
2008
with 4 others
Phase 1
14 of 78
1 open now
Registered
34th of 78
by date

Among the 78 studies testing fluorouracil in Stomach Neoplasms, this one is the 49th largest by enrollment of the 73 interventional ones that give a count, is one of 5 that started in 2008, is one of 14 in phase 1, and was the 34th registered.

Stomach Neoplasms

3,401 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 78 studies testing fluorouracil in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing fluorouracil in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safe and tolerable dose of sunitinib when given together with cisplatin and 5-fluorouracil in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.

03

Conditions studied

  • Stomach Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of stomach cancer
  • advanced stomach cancer stage IV
  • adequate blood chemistry, blood counts and kidney function
  • willing to participate to study requirements and to sign an document

Exclusion criteria

Exclusion Criteria:

  • prior chemotherapy for stomach cancer in its advanced stage
  • excessive toxicities related to prior therapies
  • pregnant or breastfeeding patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    A

    Drug: 5-fluorouracil · Drug: cisplatin · Drug: sunitinib malate

Interventions

  • 5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

  • Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

  • sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

06

What researchers measure

Primary outcomes

  1. Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)

    The incidence of DLTs assessed during the first cycle (21 days).

    Time frame: Cycle 1 (Baseline to Day 21)

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours post dose)

  2. Area Under the Curve From Time 0 to 24 Hours Postdose [AUC (0-24)]

    Area under the plasma concentration versus time curve from time 0 (pre-dose) to 24 hours postdose (0-24).

    Time frame: Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours postdose)

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Tmax is the time to first occurrence of maximum observed plasma concentration (Cmax).

    Time frame: Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours post dose)

  4. Steady State Concentration (Css) of 5-Fluorouracil (5-FU)

    Steady state plasma concentration of 5-FU equals AUC(2-6) divided by 4, where AUC(2-6) is the area under the plasma concentration versus time curve from time 2 to 6 hours postdose (2-6).

    Time frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)

  5. Infusion Rate (Zero Order) (R0) of 5-FU

    Infusion rate of 5-FU equals total dose divided by infusion time.

    Time frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)

  6. Clearance (CLss) of 5-FU

    Steady state total body clearance equals infusion rate (zero order) divided by steady state plasma concentration of 5-FU (R0/Css).

    Time frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)

  7. Area Under the Curve From Time 2 to 6 Hours Postdose [AUC (2-6)] of 5-FU

    Area under the plasma concentration versus time curve from time 2 to 6 hours postdose (2-6).

    Time frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)

  8. Number of Participants With Objective Response

    Number of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Baseline, Day 21 of every even-numbered cycle up to 15 Months

  9. Duration of Response (DR)

    Time from the first objective documentation of tumor response (confirmed or partial response) to first documented objective tumor progression or death due to any cause, whichever occurrs first. DR calculated as (Months) equals (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 30.

    Time frame: Baseline up to Month 15

  10. Progression-Free Survival (PFS)

    Median time (50%) from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (Months) equals (first event date minus first dose date plus 1) divided by 30.

    Time frame: Baseline up to Month 15

07

Results

Posted Jan 5, 2011

Participant flow

Participant flow — Overall Study
MilestoneSunitinib (25 mg) in Combination With Cisplatin and 5-FUSunitinib (37.5 mg) in Combination With Cisplatin and 5-FU
Started2410
Completed00
Not completed2410
Withdrew: Death02
Withdrew: Adverse event82
Withdrew: Objective progression or relapse115
Withdrew: Other31
Withdrew: Participant refused20

Outcome measures

PrimaryNumber of Participants With First-cycle Dose Limiting Toxicities (DLTs)

The incidence of DLTs assessed during the first cycle (21 days).

Time frame:
Cycle 1 (Baseline to Day 21)
Reported as:
Number · Participants
Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)
ParticipantsSunitinib (25 mg) in Combination With Cisplatin and 5-FUSunitinib (37.5 mg) in Combination With Cisplatin and 5-FU
Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)10
SecondaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours post dose)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax)
nanograms per milliliter (ng/mL)Sunitinib (25 mg) in Combination With Cisplatin and 5-FU
Sunitinib16.8 ± 8.19
SU012662 (metabolite of Sunitinib)2.24 ± 1.29
Total Drug (Sunitinib + SU012662)19.0 ± 9.35
SecondaryArea Under the Curve From Time 0 to 24 Hours Postdose [AUC (0-24)]

Area under the plasma concentration versus time curve from time 0 (pre-dose) to 24 hours postdose (0-24).

Time frame:
Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours postdose)
Reported as:
Mean · ng*h/mL
Area Under the Curve From Time 0 to 24 Hours Postdose [AUC (0-24)]
ng*h/mLSunitinib (25 mg) in Combination With Cisplatin and 5-FU
Sunitinib249 ± 127
SU012662 (metabolite of Sunitinib)34.0 ± 19.5
Total Drug (Sunitinib + SU012662)283 ± 144
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)

Tmax is the time to first occurrence of maximum observed plasma concentration (Cmax).

Time frame:
Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours post dose)
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hoursSunitinib (25 mg) in Combination With Cisplatin and 5-FU
Sunitinib4.00 (2.00 to 24.0)
SU012662 (metabolite of Sunitinib)4.00 (2.00 to 24.0)
Total Drug (Sunitinib + SU012662)4.00 (2.00 to 24.0)
SecondarySteady State Concentration (Css) of 5-Fluorouracil (5-FU)

Steady state plasma concentration of 5-FU equals AUC(2-6) divided by 4, where AUC(2-6) is the area under the plasma concentration versus time curve from time 2 to 6 hours postdose (2-6).

Time frame:
Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)
Reported as:
Mean · ng/mL
Steady State Concentration (Css) of 5-Fluorouracil (5-FU)
ng/mLSunitinib (25 mg) in Combination With Cisplatin and 5-FU
Steady State Concentration (Css) of 5-Fluorouracil (5-FU)593 ± 433
SecondaryInfusion Rate (Zero Order) (R0) of 5-FU

Infusion rate of 5-FU equals total dose divided by infusion time.

Time frame:
Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)
Reported as:
Mean · mg/hr
Infusion Rate (Zero Order) (R0) of 5-FU
mg/hrSunitinib (25 mg) in Combination With Cisplatin and 5-FU
Infusion Rate (Zero Order) (R0) of 5-FU68.2 ± 12.5
SecondaryClearance (CLss) of 5-FU

Steady state total body clearance equals infusion rate (zero order) divided by steady state plasma concentration of 5-FU (R0/Css).

Time frame:
Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)
Reported as:
Mean · Liters per hour
Clearance (CLss) of 5-FU
Liters per hourSunitinib (25 mg) in Combination With Cisplatin and 5-FU
Clearance (CLss) of 5-FU161 ± 93.2
SecondaryArea Under the Curve From Time 2 to 6 Hours Postdose [AUC (2-6)] of 5-FU

Area under the plasma concentration versus time curve from time 2 to 6 hours postdose (2-6).

Time frame:
Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)
Reported as:
Mean · ng*h/mL
Area Under the Curve From Time 2 to 6 Hours Postdose [AUC (2-6)] of 5-FU
ng*h/mLSunitinib (25 mg) in Combination With Cisplatin and 5-FU
Area Under the Curve From Time 2 to 6 Hours Postdose [AUC (2-6)] of 5-FU2372 ± 1729
SecondaryNumber of Participants With Objective Response

Number of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Baseline, Day 21 of every even-numbered cycle up to 15 Months
Reported as:
Number · Participants
Number of Participants With Objective Response
ParticipantsSunitinib (25 mg) in Combination With Cisplatin and 5-FUSunitinib (37.5 mg) in Combination With Cisplatin and 5-FU
Number of Participants With Objective Response63
Statistical analysis
  • Sunitinib (25 mg) in Combination With Cisplatin and 5-FU vs Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU · Fisher Exact · Objective response rate (orr) (percent): 27.3 · 95% CI 13.3 to 45.5Exact Method based on the F Distribution.
SecondaryDuration of Response (DR)

Time from the first objective documentation of tumor response (confirmed or partial response) to first documented objective tumor progression or death due to any cause, whichever occurrs first. DR calculated as (Months) equals (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 30.

Time frame:
Baseline up to Month 15
Reported as:
Mean · Months
Duration of Response (DR)
MonthsSunitinib (25 mg) in Combination With Cisplatin and 5-FUSunitinib (37.5 mg) in Combination With Cisplatin and 5-FU
Duration of Response (DR)4.17 ± 2.284.13 ± 0.73
SecondaryProgression-Free Survival (PFS)

Median time (50%) from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (Months) equals (first event date minus first dose date plus 1) divided by 30.

Time frame:
Baseline up to Month 15
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsSunitinib (25 mg) in Combination With Cisplatin and 5-FUSunitinib (37.5 mg) in Combination With Cisplatin and 5-FU
Progression-Free Survival (PFS)5.2 (3.8 to 7.6)6.2 (3.3 to 6.9)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sunitinib (25 mg) in Combination With Cisplatin and 5-FU—7/24 (29.2%)24/24 (100%)
Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU—5/10 (50%)10/10 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventSunitinib (25 mg) in Combination With Cisplatin and 5-FUSunitinib (37.5 mg) in Combination With Cisplatin and 5-FU
Mucosal inflammationGeneral disorders0/243/10
Febrile neutropeniaBlood and lymphatic system disorders1/242/10
AnaemiaBlood and lymphatic system disorders0/241/10
DiarrhoeaGastrointestinal disorders0/241/10
OesophagitisGastrointestinal disorders0/241/10
VomitingGastrointestinal disorders0/241/10
Device occlusionGeneral disorders0/241/10
Disease progressionGeneral disorders0/241/10
FatigueGeneral disorders0/241/10
RashSkin and subcutaneous tissue disorders0/241/10
Most frequent other events
Showing 10 of 101
Most frequent other events
EventSunitinib (25 mg) in Combination With Cisplatin and 5-FUSunitinib (37.5 mg) in Combination With Cisplatin and 5-FU
NeutropeniaBlood and lymphatic system disorders21/2410/10
VomitingGastrointestinal disorders13/249/10
Mucosal inflammationGeneral disorders19/248/10
AstheniaGeneral disorders19/247/10
Decreased appetiteMetabolism and nutrition disorders12/247/10
AnaemiaBlood and lymphatic system disorders12/246/10
NauseaGastrointestinal disorders14/244/10
ThrombocytopeniaBlood and lymphatic system disorders6/245/10
FatigueGeneral disorders1/245/10
Abdominal pain upperGastrointestinal disorders6/244/10

Baseline characteristics

Age Continuous
Age Continuous(years)Sunitinib (25 mg) in Combination With Cisplatin and 5-FUSunitinib (37.5 mg) in Combination With Cisplatin and 5-FUTotal
Mean60.1 ± 12.056.4 ± 10.459.0 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Sunitinib (25 mg) in Combination With Cisplatin and 5-FUSunitinib (37.5 mg) in Combination With Cisplatin and 5-FUTotal
Female7411
Male17623
08

Study locations

3 sites
  • Pfizer Investigational Site
    L'hospitalet de Llobregat, Barcelona 08907, Spain
  • Pfizer Investigational Site
    Barcelona, 08003, Spain
  • Pfizer Investigational Site
    Madrid, 28041, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Dec 2009 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2007
First posted
Nov 9, 2007
Start
Aug 2008
Primary completionActual
Dec 2009
CompletionActual
Aug 2010
Results first posted
Jan 5, 2011
Last update
Dec 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00555672
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 9, 2007
Start date
Aug 2008
Primary completion
Dec 2009
Completion
Aug 2010
Results posted
Jan 5, 2011
Last update
Dec 19, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Cisplatin · Sunitinib

Start the discussion